KBP-8044

KBP-8044 is an investigational small molecule drug candidate developed by KBP BioSciences for the treatment of kidney fibrosis. As a new chemical entity (NCE), it is designed to target the pathological processes involved in the progression of renal scarring and the accumulation of extracellular matrix, which are hallmarks of chronic kidney disease (CKD). The drug is part of KBP BioSciences' pipeline focused on cardiorenal and infectious diseases, utilizing their platform for organ-targeting small molecules. While the specific molecular target of KBP-8044 has not been publicly disclosed, it is intended to provide a therapeutic intervention to slow or reverse the fibrotic damage that leads to end-stage renal disease.